이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Hansa Biopharma 관리

관리 기준 확인 3/4

Hansa Biopharma's CEO는 Søren Tulstrup, Mar2018 에 임명되었습니다 의 임기는 6.25 년입니다. 총 연간 보상은 SEK 27.51M, 30.7% 로 구성됩니다. 30.7% 급여 및 69.3% 보너스(회사 주식 및 옵션 포함). 는 $ 157.52K 가치에 해당하는 회사 주식의 0.05% 직접 소유합니다. 157.52K. 경영진과 이사회의 평균 재임 기간은 각각 4.2 년과 5.1 년입니다.

주요 정보

Søren Tulstrup

최고 경영자

SEK 27.5m

총 보상

CEO 급여 비율	30.7%
CEO 임기	6.3yrs
CEO 소유권	0.05%
경영진 평균 재임 기간	4.2yrs
이사회 평균 재임 기간	5.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Søren Tulstrup 의 보수는 Hansa Biopharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-SEK 845m
Dec 31 2023	SEK 28m	SEK 8m	-SEK 832m
Sep 30 2023	n/a	n/a	-SEK 856m
Jun 30 2023	n/a	n/a	-SEK 759m
Mar 31 2023	n/a	n/a	-SEK 678m
Dec 31 2022	SEK 26m	SEK 8m	-SEK 611m
Sep 30 2022	n/a	n/a	-SEK 626m
Jun 30 2022	n/a	n/a	-SEK 620m
Mar 31 2022	n/a	n/a	-SEK 583m
Dec 31 2021	SEK 26m	SEK 7m	-SEK 548m
Sep 30 2021	n/a	n/a	-SEK 491m
Jun 30 2021	n/a	n/a	-SEK 465m
Mar 31 2021	n/a	n/a	-SEK 431m
Dec 31 2020	SEK 21m	SEK 6m	-SEK 421m
Sep 30 2020	n/a	n/a	-SEK 426m
Jun 30 2020	n/a	n/a	-SEK 398m
Mar 31 2020	n/a	n/a	-SEK 381m
Dec 31 2019	SEK 11m	SEK 5m	-SEK 360m
Sep 30 2019	n/a	n/a	-SEK 330m
Jun 30 2019	n/a	n/a	-SEK 298m
Mar 31 2019	n/a	n/a	-SEK 274m
Dec 31 2018	SEK 8m	SEK 4m	-SEK 248m

보상 대 시장: Søren 의 총 보상 ($USD 2.62M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.46M ).

보상과 수익: 회사가 수익성이 없는 동안 Søren 의 보상이 증가했습니다.

CEO

Søren Tulstrup (59 yo)

6.3yrs

테뉴어

SEK 27,505,000

보상

Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Biopharma AB (publ) (formerly known as Hansa Medical AB (publ)) since March 20, 2018. Mr. Tulstrup served as the Chief Exec...

리더십 팀

이름	위치	테뉴어	보상	소유권
Søren Tulstrup	President & CEO	6.3yrs	SEK 27.51m	0.050% SEK 157.5k
C. Ballantyne	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Christian Kjellman	Senior VP & COO	4.4yrs	데이터 없음	데이터 없음
Hitto Kaufmann	Chief Scientific Officer	less than a year	데이터 없음	데이터 없음
Eva-Maria Joed	Vice President of Finance & Administration	5.1yrs	데이터 없음	데이터 없음
Klaus Sindahl	VP & Head of Investor Relations	no data	데이터 없음	데이터 없음
Anne Lanner	Senior VP & Chief Human Resources Officer	5.4yrs	데이터 없음	데이터 없음
Emanuel Björne	VP & Head of Business Development	no data	데이터 없음	데이터 없음
Lena Winstedt	Head of Science	no data	데이터 없음	데이터 없음
Vincenza Nigro	VP & Head of Medical Affairs	no data	데이터 없음	데이터 없음
Achim Kaufhold	Senior VP & Chief Medical Officer	4yrs	데이터 없음	데이터 없음
Magnus Korsgren	VP & Head of Research and Development	3.2yrs	데이터 없음	데이터 없음

4.2yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: HNSB.F 의 관리팀은 경험 ( 4.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Anders Pedersen	Independent Director	6.1yrs	SEK 413.00k	0.0040% SEK 12.5k
Mats Blom	Independent Director	5.1yrs	SEK 493.00k	0.0016% SEK 5.0k
Peter Nicklin	Independent Chairman of the Board	2yrs	SEK 1.14m	0.039% SEK 122.4k
Eva Nilsagard	Independent Director	5.1yrs	SEK 591.00k	0.0047% SEK 15.0k
Hilary Malone	Independent Director	3.1yrs	SEK 725.00k	데이터 없음
Andreas Eggert	Independent Director	6.1yrs	SEK 595.00k	0.0087% SEK 27.5k
Gunnar Tufveson	Chairman of European Medical Advisory Board in Transplantation	no data	데이터 없음	데이터 없음
Kathryn Wood	Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation	no data	데이터 없음	데이터 없음
Christophe Legendre	Member of European Medical Advisory Board in Transplantation	no data	데이터 없음	데이터 없음
Stanley Jordan	Chairman of US Medical Advisory Board in Transplantation	no data	데이터 없음	데이터 없음
Robert Montgomery	Member of US Medical Advisory Board in Transplantation	no data	데이터 없음	데이터 없음

5.1yrs

평균 재임 기간

59.5yo

평균 연령

경험이 풍부한 이사회: HNSB.F 의 이사회는 경험(평균 재직 기간 5.1 년)으로 간주됩니다.

Hansa Biopharma 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Hansa Biopharma AB (publ) Announces Board Appointments

Hansa Biopharma AB (Publ) Announces CFO Changes

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma Nomination Committee Formed

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Recent updates

Hansa Biopharma AB (publ) to Report Nine Months, 2025 Results on Oct 23, 2025

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Hansa Biopharma AB (publ) to Report Q1, 2025 Results on Apr 17, 2025

Hansa Biopharma AB (publ) Announces Board Appointments

Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Hansa Biopharma AB (Publ) Announces CFO Changes

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma AB (publ) Announces Formation of Nomination Committee

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering.

Hansa Biopharma AB (Publ) Announces Positive Reimbursement Decision in Italy for Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

Hansa Biopharma AB Announces Positive Topline Data from the Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

The Scottish Medicines Consortium Recommends Use of Hansa Biopharma's Idefirix[®] (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.

Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Appoints Peter Nicklin as A New Member of the Board of Director

NICE Recommends Use of Hansa Biopharma's Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Announces Ulf Wiinberg Not to Stand for Re-Election as Director

Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma Announces Temporary Marketing Authorization in Switzerland for Idefirix (Imlifidase) in Kidney Transplantation

Hansa Biopharma Announces U.S. Fda Acceptance of Investigational New Drug (Ind) Application for Phase 3 Study of Imlifidase in Anti-Gbm Disease

Hansa Biopharma AB and Medison Pharma Announces Marketing Authorization in Israel for Idefirix for Desensitization Treatment of Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB Announces Grant of Early Access Post Marketing Authorization for its First-In-Class Treatment Idefirix® (imlifidase)

Hansa Biopharma AB Announces Positive Early Access Decision by French Haute Autorité De Santé to Use Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Enrolls First Patient in U.S. Randomized, Controlled Pivotal Trial of imlifidase in Highly Sensitized Kidney Transplant Patients

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령